Mouse Anti-Human IgA1-BIOT
Référence 9130-08
Conditionnement : 0.5mg
Marque : Southern Biotech
Clone | B3506B4 |
---|---|
Isotype | Mouse IgG1κ |
Isotype Control | Mouse IgG1-BIOT (15H6) |
Specificity | Human IgA1 Fc |
Immunogen | Fc fragment of human IgA1 myeloma protein |
Conjugate | BIOT (Biotin) |
Buffer Formulation | Phosphate buffered saline containing < 0.1% sodium azide |
Clonality | Monoclonal |
Concentration | 0.5 mg/mL |
Volume | 1.0 mL |
Recommended Storage | 2-8°C |
Applications | ELISA – Quality tested 1-9 FLISA – Quality tested ELISpot – Reported in literature 10 Flow Cytometry – Reported in literature 6,16 Immunohistochemistry-Frozen Sections – Reported in literature 6,11 Immunocytochemistry – Reported in literature 6,12 Western Blot – Reported in literature 13-15 Multiplex – Reported in literature 17-20 Separation – Reported in literature 6 Depletion – Reported in literature 21 |
RRID Number | AB_2796655 |
Gene ID | 3493 (Human) |
Gene ID Symbol | IGHA1 (Human) |
Gene ID Aliases | IgA1 |
UniProt ID | P01876 (Human |
UniProt Name | IGHA1_HUMAN (Human) |
Documentation
Technical Bulletin Safety Datasheet
Certificate of Analysis Lookup
Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view
- 1. Johnson S, Sypura WD, Gerding DN, Ewing SL, Janoff EN. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease. Infect Immun. 1995;63:3166-73. (ELISA)
- 2. Opstad NL, Daley CL, Thurn JR, Rubins JB, Merrifield C, Hopewell PC, et al. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. J Infect Dis. 1995;172:566-70. (ELISA)
- 3. Camacho MT, Outschoorn I, Kovácová E, Telléz A. Distribution of immunoglobulin G (IgG) and A (IgA) subclasses following Q fever vaccination with soluble phase I Coxiella burnetii extract. Vaccine. 2000;18:1773-7. (ELISA)
- 4. Azim T, Zaki MH, Podder G, Sultana N, Salam MA, Rahman SM, et al. Rotavirus-specific subclass antibody and cytokine responses in Bangladeshi children with rotavirus diarrhoea. J Med Virol. 2003;69:286-95. (ELISA)
- 5. Arnold M, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288-96. (ELISA)
- 6. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, et al. Intestinal bacteria trigger T cell-independent immunoglobulin A2 class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity. 2007;26:812-26. (ELISA, Sep, FC, IHC-FS, ICC)
- 7. Fasching CE, Grossman T, Corthésy B, Plaut AG, Weiser JN, Janoff EN. Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. Infect Immun. 2007;75:1801-10. (ELISA)
- 8. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis. 2012;206:1836-43. (ELISA)
- 9. Shao J, Peng Y, He L, Liu H, Chen X, Peng X. Capsaicin induces high expression of BAFF and aberrantly glycosylated IgA1 of tonsillar mononuclear cells in IgA nephropathy patients. Hum Immunol. 2014;75:1034-9. (ELISA)
- 10. Carson PJ, Schut RL, Simpson ML, O'Brien J, Janoff EN. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. J Infect Dis. 1995;172:340-5. (ELISPOT)
- 11. Senpuku H, Asano T, Matin K, Salam MA, Tsuha Y, Horibata S, et al. Effects of human interleukin-18 and interleukin-12 treatment on human lymphocyte engraftment in NOD-scid mouse. Immunology. 2002;107:232-42. (IHC-FS)
- 12. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118:629-39. (ICC)
- 13. Batten MR, Senior BW, Kilian M, Woof JM. Amino acid sequence requirements in the hinge of human immunoglobulin A1 (IgA1) for cleavage by streptococcal IgA1 proteases. Infect Immun. 2003;71:1462-9. (WB)
- 14. Lewis MJ, Pleass RJ, Batten MR, Atkin JD, Woof JM. Structural requirements for the interaction of human IgA with the human polymeric Ig receptor. J Immunol. 2005;175:6694-701. (WB)
- 15. Lehoux S, Mi R, Aryal RP, Wang Y, Schjoldager KT, Clausen H, et al. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals. Mol Cell Proteomics. 2014;13:3097-113. (WB)
- 16. Avery DT, Bryant VL, Ma CS, de Waal Malefyt R, Tangye SG. IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4. J Immunol. 2008;181:1767-79. (FC)
- 17. Arnold M, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens. 2008;72:60-6. (Multiplex)
- 18. Keynan Y, Bodnarchuk T, Wayne S, Li Y, Fowke KR. Evaluation of influenza-specific humoral response by microbead array analysis. Can J Infect Dis Med Microbiol. 2011;22:25-9. (Multiplex)
- 19. Arnold M, Heinemann FM, Horn P, Ziemann M, Lachmann N, Mühlbacher A, et al. 16th IHIW: anti-HLA alloantibodies of the of IgA isotype in re-transplant candidates. Int J Immunogenet. 2013;40:17-20. (Multiplex)
- 20. Arnold M, Ntokou I, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int. 2014;27:253-61. (Multiplex)
- 21. Kitani A, Strober W. Differential regulation of Cα1 and Cα2 germ-line and mature mRNA transcripts in human peripheral blood B cells. J Immunol. 1994;153:1466-77. (Depletion)